Material-Encoded Synchronization of Immunogenic Cell Death With Adenosine A2A Receptor Blockade Reprograms the Tumor...

Area of Science:

• Biomedical Engineering
• Cancer Immunology
• Nanomedicine

Background:

• Adenosine suppresses antitumor immunity via the adenosine A2A receptor (A2AR).
• Immunogenic cell death (ICD) releases ATP, which converts to immunosuppressive adenosine.
• Synchronizing ICD and A2AR blockade is crucial for effective cancer immunotherapy.

Purpose of the Study:

• To design a nanomedicine (BSCS@PHY) that simultaneously induces ICD and blocks local A2AR signaling.
• To protect anti-tumor immune responses from adenosine-mediated suppression.
• To enhance antigen priming and T-cell responses within the tumor microenvironment.

Main Methods:

• BSCS@PHY integrates a bismuth-copper diselenide core, phase-change materials, A2AR antagonist SCH442416, and yeast cell wall components.
• Thermography-guided irradiation activates the nanomedicine, inducing ICD and releasing the antagonist.
• Chemodynamic therapy and photothermal therapy were employed for synergistic effects.

Main Results:

• BSCS@PHY demonstrated image-guided activation, enhanced ICD hallmarks, and reduced adenosine signaling in 4T1 tumors.
• The therapy promoted dendritic-cell maturation and T-cell priming, leading to improved tumor control.
• Combined treatment with anti-PD-L1 showed additive therapeutic benefits.

Conclusions:

• The material-encoded strategy effectively synchronizes ICD induction with local A2AR blockade.
• BSCS@PHY offers a promising framework for enhancing immunotherapy in 'cold' tumors by targeting metabolic checkpoints.
• Both A2AR blockade and yeast cell wall-mediated adjuvanticity play critical, non-redundant roles in the observed efficacy.